JNJ raises 2026 revenue growth guidance to 6.1%, targets $100 billion in annual revenue

Earnings
โดย Yahoo Finance·Read original
Summary · why it matters

Johnson & Johnson raised its 2026 revenue growth guidance to 6.1% on April 14, 2026, and stated it is on track to reach $100 billion in annual revenue for the first time, framing the business as an accelerating growth story. Despite the raised outlook, the stock has gained only 6.4% since the announcement, suggesting investors are waiting for more proof before pricing in a new era of growth. Options traders are pricing in implied volatility of 22% for JNJ, in the 80th percentile of its one-year range, signaling expectations for a larger-than-normal swing around the next earnings report. The company, with a market cap of about $611 billion, says it has a line of sight to double-digit growth by the end of the decade.

Impact on stocks 8

Biotech & Genomic Medicine · 5 stocks
Johnson & Johnson
JNJ
▲ PositiveCapitalrelevance

JNJ raised its 2026 revenue growth guidance to 6.1% and targets $100 billion in annual revenue, a positive financial outlook.

Artificial Intelligence · 2 stocks
Robotics & Physical AI · 1 stocks